XWELL, Inc. (XWEL)
NASDAQ: XWEL · Real-Time Price · USD
1.745
-0.045 (-2.50%)
Nov 4, 2024, 4:00 PM EST - Market closed
XWELL Revenue
XWELL had revenue of $9.28M in the quarter ending June 30, 2024, with 13.54% growth. This brings the company's revenue in the last twelve months to $32.88M, down -1.95% year-over-year. In the year 2023, XWELL had annual revenue of $30.11M, down -46.18%.
Revenue (ttm)
$32.88M
Revenue Growth
-1.95%
P/S Ratio
0.22
Revenue / Employee
$97,564
Employees
337
Market Cap
9.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 30.11M | -25.83M | -46.18% |
Dec 31, 2022 | 55.94M | -17.79M | -24.13% |
Dec 31, 2021 | 73.73M | 65.34M | 779.30% |
Dec 31, 2020 | 8.39M | -38.92M | -82.28% |
Dec 31, 2019 | 47.31M | -2.34M | -4.70% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Streamline Health Solutions | 20.30M |
Precipio | 16.72M |
Ensysce Biosciences | 1.44M |
Addex Therapeutics | 960.64K |
Soligenix | 494.62K |
Virax Biolabs Group | 156.42K |
XWEL News
- 7 weeks ago - ThredUp And 2 Other Stocks Under $2 Executives Are Buying - Benzinga
- 2 months ago - XWELL Appoints Ezra Ernst as New President and Chief Executive Officer - GlobeNewsWire
- 2 months ago - XWELL Announces Partnership with Priority Pass - GlobeNewsWire
- 2 months ago - XWELL, Inc. Adopts Tax Benefits Preservation Plan - GlobeNewsWire
- 2 months ago - XWELL, Inc. Reports Second Quarter 2024 Results - GlobeNewsWire
- 2 months ago - XWELL Comments on CPC's Withdrawal of Threatened Proxy Fight and Related Lawsuit - GlobeNewsWire
- 3 months ago - XWELL Announces Closing of $1.4 Million Registered Direct Offering Priced At Premium to Market - GlobeNewsWire
- 3 months ago - CPC Issues Letter to Fellow XWELL, Inc. Shareholders Revealing Intention Behind Recent Schedule 13D Filing & Lawsuit Against Entrenched Board of Directors - GlobeNewsWire